[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2012000391A1 - Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina. - Google Patents

Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina.

Info

Publication number
CL2012000391A1
CL2012000391A1 CL2012000391A CL2012000391A CL2012000391A1 CL 2012000391 A1 CL2012000391 A1 CL 2012000391A1 CL 2012000391 A CL2012000391 A CL 2012000391A CL 2012000391 A CL2012000391 A CL 2012000391A CL 2012000391 A1 CL2012000391 A1 CL 2012000391A1
Authority
CL
Chile
Prior art keywords
amount
asn297
bendamustine
oligosaccharides
antibody
Prior art date
Application number
CL2012000391A
Other languages
English (en)
Inventor
Frank Herting
Christian Klein
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CL2012000391A1 publication Critical patent/CL2012000391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2012000391A 2009-08-14 2012-02-14 Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina. CL2012000391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14

Publications (1)

Publication Number Publication Date
CL2012000391A1 true CL2012000391A1 (es) 2012-08-24

Family

ID=41351729

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000391A CL2012000391A1 (es) 2009-08-14 2012-02-14 Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina.

Country Status (34)

Country Link
US (4) US20110165151A1 (es)
EP (1) EP2464382B1 (es)
JP (3) JP5646626B2 (es)
KR (1) KR101425736B1 (es)
CN (2) CN107261138A (es)
AR (1) AR077866A1 (es)
AU (1) AU2010281866B2 (es)
BR (1) BR112012002855A2 (es)
CA (1) CA2769674C (es)
CL (1) CL2012000391A1 (es)
CR (1) CR20120036A (es)
CY (2) CY1119251T1 (es)
DK (1) DK2464382T3 (es)
ES (1) ES2630158T3 (es)
HK (1) HK1245145A1 (es)
HR (1) HRP20170972T1 (es)
HU (2) HUE033531T2 (es)
IL (1) IL217753A (es)
LT (2) LT2464382T (es)
LU (1) LUC00045I2 (es)
MA (1) MA33469B1 (es)
MX (2) MX355849B (es)
MY (1) MY163003A (es)
NO (1) NO2017054I1 (es)
NZ (1) NZ597666A (es)
PL (1) PL2464382T3 (es)
PT (1) PT2464382T (es)
RS (1) RS56146B1 (es)
SG (1) SG178324A1 (es)
SI (1) SI2464382T1 (es)
TW (1) TWI409079B (es)
UA (1) UA110096C2 (es)
WO (1) WO2011018224A1 (es)
ZA (1) ZA201200830B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101220691B1 (ko) 2003-11-05 2013-01-14 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진ｃｄ20 항체
TWI439286B (zh) 2007-07-16 2014-06-01 Genentech Inc 抗－ｃｄ７９ｂ抗體及免疫共軛物及使用方法
JP2010533495A (ja) 2007-07-16 2010-10-28 ジェネンテック， インコーポレイテッド ヒト化ＣＤ７９ｂ抗体およびイムノコンジュゲートならびにそれらの使用
EP4427805A2 (en) 2008-01-31 2024-09-11 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
SG10201503991SA (en) 2010-05-31 2015-07-30 Ono Pharmaceutical Co Purinone derivative
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
HUE058350T2 (hu) * 2011-08-16 2022-07-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és nitrogénmustár alkalmazásával
ES2909720T3 (es) * 2011-08-16 2022-05-10 Morphosys Ag Terapia de combinación con un anticuerpo anti-CD19 y un análogo de purina
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
EP2786996B1 (en) 2011-11-29 2016-09-14 ONO Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
UA119443C2 (uk) 2013-06-07 2019-06-25 Нордік Нановектор Аса Спосіб підвищення регуляції експресії антигену
US9416131B2 (en) 2014-03-25 2016-08-16 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma
CA3069221C (en) 2014-09-23 2023-04-04 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
US10239879B2 (en) 2015-04-09 2019-03-26 Ono Pharmaceutical Co., Ltd. Process for producing purinone derivative
DK3331910T3 (da) 2015-08-03 2020-03-16 Engmab Sarl Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma)
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
BR112019008426A2 (pt) 2016-11-02 2019-09-03 Engmab Sarl anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
ES2945214T3 (es) 2018-05-23 2023-06-29 Celgene Corp Compuestos antiproliferativos y anticuerpo biespecífico contra BCMA y CD3 para uso combinado
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
JP2002515511A (ja) 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
JP4368530B2 (ja) 1999-04-09 2009-11-18 協和発酵キリン株式会社 免疫機能分子の活性を調節する方法
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
CZ308720B6 (cs) 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
AU2004241093B2 (en) * 2003-05-16 2009-08-27 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US20050054048A1 (en) 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
JP2007503206A (ja) 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
WO2005027966A2 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
KR101220691B1 (ko) 2003-11-05 2013-01-14 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진ｃｄ20 항체
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP1877441A2 (en) 2005-04-26 2008-01-16 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
CN101291954B (zh) 2005-08-26 2013-03-27 罗氏格黎卡特股份公司 具有改变的细胞信号传导活性的修饰的抗原结合分子
EP2388273B1 (en) * 2005-10-21 2017-07-05 LFB USA, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
CA2749151A1 (en) * 2009-01-16 2010-07-22 Glaxosmithkline Llc Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
CN102395619B (zh) * 2009-04-15 2013-06-12 因温斯特技术公司 改进否则不溶混的化合物的溶混性

Also Published As

Publication number Publication date
EP2464382B1 (en) 2017-05-03
RU2012109445A (ru) 2013-09-27
US20160166688A9 (en) 2016-06-16
US20150093376A1 (en) 2015-04-02
AU2010281866A1 (en) 2012-02-02
LUC00045I2 (es) 2018-02-26
KR20120054068A (ko) 2012-05-29
TW201110980A (en) 2011-04-01
ZA201200830B (en) 2012-10-31
UA110096C2 (uk) 2015-11-25
CY2017034I1 (el) 2018-02-14
NZ597666A (en) 2013-10-25
CA2769674C (en) 2018-01-23
RS56146B1 (sr) 2017-11-30
CN102596245A (zh) 2012-07-18
HUS000498I2 (hu) 2021-03-29
JP2015071611A (ja) 2015-04-16
BR112012002855A2 (pt) 2016-11-01
TWI409079B (zh) 2013-09-21
SG178324A1 (en) 2012-03-29
HUS1700041I1 (hu) 2017-11-28
LTPA2017035I1 (lt) 2017-11-27
WO2011018224A1 (en) 2011-02-17
IL217753A0 (en) 2012-03-29
CN107261138A (zh) 2017-10-20
MY163003A (en) 2017-07-31
JP5963013B2 (ja) 2016-08-03
JP2016222673A (ja) 2016-12-28
HRP20170972T1 (hr) 2017-09-22
HUE033531T2 (hu) 2021-12-28
SI2464382T1 (sl) 2017-08-31
US20110165151A1 (en) 2011-07-07
MA33469B1 (fr) 2012-07-03
JP2013501740A (ja) 2013-01-17
MX355849B (es) 2018-05-02
JP5646626B2 (ja) 2014-12-24
HK1245145A1 (zh) 2018-08-24
ES2630158T3 (es) 2017-08-18
CA2769674A1 (en) 2011-02-17
CY1119251T1 (el) 2018-02-14
NO2017054I1 (no) 2017-10-26
AU2010281866B2 (en) 2016-05-12
CR20120036A (es) 2012-04-18
CY2017034I2 (el) 2018-02-14
IL217753A (en) 2016-10-31
US20120315268A1 (en) 2012-12-13
US20140044705A1 (en) 2014-02-13
EP2464382A1 (en) 2012-06-20
DK2464382T3 (en) 2017-07-17
MX2012001782A (es) 2012-04-19
PT2464382T (pt) 2017-06-30
PL2464382T3 (pl) 2017-09-29
LUC00045I1 (es) 2017-11-03
AR077866A1 (es) 2011-09-28
KR101425736B1 (ko) 2014-08-01
LT2464382T (lt) 2017-07-25

Similar Documents

Publication Publication Date Title
CL2012000391A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos de la cantidad total de oligosacaridos en asn297 para tratar cancer en combinacion con bendamustina.
CL2012000392A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos para tratar cancer en combinacion con fludarabina .
SG10201610247QA (en) Antibody variants having modifications in the constant region
BRPI1009824A2 (pt) dispersão sólida e forma farmacêutica sólida.
EP2538976B8 (en) Immunoconjugates against folate receptor 1 and uses thereof
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
BR112013014522A2 (pt) anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
PL2256371T3 (pl) Dwustronny gwintowany korpus
FI20085213A (fi) Pigmenttipartikkelikoostumus, menetelmä sen valmistamiseksi sekä sen käyttö
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
EP2354161A4 (en) ANTI-NR10 ANTIBODIES AND CORRESPONDING USE
BRPI0923859A2 (pt) Nanopartícula, composição, métodos para a produção das nanopartículas e de uso, e, uso de nanopartículas.
BR112012005208A2 (pt) antiocorpos contra o receptor de glucagon e seu uso
HK1156333A1 (zh) 種硫酸化多聚糖化合物及其製備方法和用途
AR082693A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
GB0813974D0 (en) Saftey lighting
BRPI0916266A2 (pt) estrutura sintética para redemoinhos assimétricos no oceano
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
GB0813973D0 (en) Saftey lighting
FI20085580A (fi) Sovitelma ALD-reaktorin yhteydessä
IL207647A0 (en) Use of interleukin-1 conjugates in the treatment of diabetes
HK1193608A1 (zh) 閃光和輝光 -二氧雜環丁烷類
BRPI0823334A2 (pt) Conexoes rosqueadas no campo petrolifero
IT1391175B1 (it) Derivati del bifluorenilidene, loro preparazione e loro uso
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.